Anacor Pharmaceuticals Stock Rating Reaffirmed by Jefferies Group (ANAC)
Anacor Pharmaceuticals (NASDAQ:ANAC)‘s stock had its “buy” rating reaffirmed by stock analysts at Jefferies Group in a report issued on Friday. They currently have a $25.00 price objective on the stock, up from their previous price objective of $24.00. Jefferies Group’s target price suggests a potential upside of 40.29% from the stock’s previous close.
Shares of Anacor Pharmaceuticals (NASDAQ:ANAC) traded up 1.01% during mid-day trading on Friday, hitting $18.00. 149,678 shares of the company’s stock traded hands. Anacor Pharmaceuticals has a 1-year low of $7.58 and a 1-year high of $23.07. The stock has a 50-day moving average of $17.1 and a 200-day moving average of $17.59. The company has a market cap of $754.4 million and a price-to-earnings ratio of 9.48.
Anacor Pharmaceuticals (NASDAQ:ANAC) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.05. The company had revenue of $2.90 million for the quarter, compared to the consensus estimate of $3.03 million. During the same quarter last year, the company posted ($0.36) earnings per share. Anacor Pharmaceuticals’s revenue was down 14.7% compared to the same quarter last year. Analysts expect that Anacor Pharmaceuticals will post $-2.20 EPS for the current fiscal year.
Anacor Pharmaceuticals Inc is a United States-based biopharmaceutical company focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.